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Context: Previous studies of menopausal age and length of reproductive life on bone are limited
by retrospective reproductive histories, being cross-sectional, or lacking gold standard bone tech-
nologies or information on hormone replacement therapy (HRT) or surgical treatment.
Objective: The objective of the studywas to investigate age atmenopause, length of reproductive
life, andHRTuse in relation to volumetric andareal bonemineral density (vBMD,aBMD), bone size,
and strength in women aged 60–64 years.
Design: This was a birth cohort study that followed up for 64 years with prospective measures of
age at menarche and menopause and monthly HRT histories.
Setting: The study was conducted in England, Scotland, and Wales.
Participants: Participants included 848 women with a known type of menopause and bone mea-
sures at 60–64 years.
Main Outcome Measures: Peripheral quantitative computed tomography measurements of the
distal radius total and trabecular vBMD were measured. Diaphyseal radius total and medullary
cross-sectional area, cortical vBMD, and polar strength strain index (SSI); dual-energy x-ray ab-
sorptiometry measurements of aBMD at the lumbar spine and total hip were also measured.
Results:A10-year increase inageatnatural (butnot surgical)menopausewasassociatedwith8.2%
(95% confidence interval [CI] 1.3%–15.1%, P .02) greater trabecular vBMD and a 6.0% (95% CI
0.51%–11.5%, P  .03) greater total vBMD; findings were similar for length of reproductive life.
A 10-year difference in HRT use was associated with a 6.0% (95% CI 2.6%–9.3%, P .001) greater
polar SSI anda 0.9% (95%CI 0.4%–1.5%, P .001) greater cortical vBMD. These estimates changed
little on adjustment. Estimates for aBMD were consistent with those for peripheral quantitative
computed tomography.
Conclusions: The positive effects on trabecular vBMD of later natural menopause and longer
reproductive life persisted into early old age. HRT use was associated with greater radius cortical
vBMD and polar SSI and aBMD. (J Clin Endocrinol Metab 101: 3827–3837, 2016)
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Hip fractures are an important cause of morbidity andmortality in older women, one of the main risk fac-
tors for which is low bone mineral density (BMD) (1).
Over the last 25years, earlier timingof naturalmenopause
has been related to lower BMD or subsequent fracture in
a number of studies (for example, references 2–6). Some
studies have investigated whether the length of reproduc-
tive life (2, 7, 8) or oophorectomy and/or hysterectomy
(9–12) are associatedwith lowerBMDor fracture, and the
findings have been somewhat less consistent. In the UK
MillionWomen Study, postmenopausal women had dou-
ble the risk of hip fracture compared with premenopausal
of the same age; however, in olderwomen, current age had
amuchgreater predictive value thanage atmenopause (5).
It is essential to take account of hormone replacement
therapy (HRT) because patterns of use vary considerably
by type and timing of menopause, and HRT is associated
with bone health. The Women’s Health Initiative trial
demonstrated that estrogen plus progestin for healthy
womenwith an intact uterus, and estrogen alone for those
with a prior hysterectomy, increased areal BMD (aBMD)
and reduced fracture risk (13, 14).However, protection of
aBMD and hip fracture starts soon after initiating HRT
but does not continue afterHRTceases (15–17). In a study
of monozygotic twins comparing pairs in which one twin
tookHRTand theother didnot,HRTwas associatedwith
greater volumetric BMD (vBMD) and bone strength at
both distal and diaphyseal bone sites (18).
Many previous studies rely on long-term recall of age at
menopause, are confounded by age, are cross-sectional or
have short follow-up, rely solely on dual-energy x-ray ab-
sorptiometry (DXA) or older quantitative bone technol-
ogies, or lack information on HRT use and other poten-
tially important confounders ormodifiers such as surgical
treatment. It also remains unclear whether associations
between age atmenopause andbonehealth persist once all
women are postmenopausal.
The Medical Research Council National Survey of
Health and Development (NSHD), a British birth cohort
study with frequent data collections from birth, fills these
research gaps because it has prospectively ascertained in-
formation on length of reproductive life and type and tim-
ing of menopause (19, 20) and HRT use (21) on a large
sample of postmenopausal women of the same age with
detailed characterization of bone health from DXA and
peripheral quantitative computed tomography (pQCT)
scans undertaken 10 years after the average age of natural
menopause.Useof pQCTallows separatemeasurementof
trabecular andcortical bone.We investigated the timingof
the menopause transition, length of reproductive life, and
patterns of HRT use in relation to pQCT- and DXA-de-
rived bone outcomes, taking account of current body size,
smoking, and socioeconomic circumstances. We hypoth-
esized that earlier age at natural menopause and a shorter
length of reproductive life would be negatively associated
with trabecular vBMD, whereas HRT use would also be
associated with greater cortical bone and bone strength
(18, 22).
Materials and Methods
Sample
The NSHD is a prospective study of 2547 women and 2815
men followed up 24 times since their birth in a week in March
1946 (23), with a further nine postal questionnaires to women
duringmidlife (19).At age60–64years, 2856 studymembers (of
whom 1460 were women) still alive and living at a known ad-
dress in England, Scotland, or Wales were invited to one of six
clinical research facilities (CRFs) across the country; the remain-
ing women were not invited because they had already died (n
312), were living abroad (n  258), had previously withdrawn
fromthe study (n284), orhadbeen lost to follow-up (n233).
Of thewomen invited, 1162 (79.6%)were assessed: 877women
had a clinic visit, with the remaining 285 women opting for a
homevisit (24).The study receivedMulti-CentreResearchEthics
Committee approval and informed consent was provided by
participants.
Of those attending a CRF, 866 women underwent a DXA
scan (QDR4500Discovery;Hologic Inc), ofwhom697 also had
a pQCT scan (XCT 2000; Stratec). Details of scan acquisition,
data management, cross-calibration, and QA/QC have been de-
scribed previously (25). Repeat precision was determined in one
center and was less than 1% for DXA measurements and for
pQCT ranged between 1% and 3%. The bone outcomes were
pQCT-derived measures at the radius distal 4% site of total and
trabecular vBMDandat the 50%site of diaphysis andmedullary
cross-sectional area (CSA), cortical vBMD and polar strength
strain index (SSI), an estimate of torsional bone strength (26),
andDXA-derivedmeasurements of aBMDfor lumbar spine (L1-
L4) and total hip.
Timing of menopause
Information onmenstrual irregularity,month and year of last
menstrual cycle or any operation to remove the uterus or ovaries,
and monthly HRT use was obtained from annual postal ques-
tionnaires between ages 47 and 54 years (inclusive) with an ad-
ditional one at 57 years and from face-to-face interviews with
trained researchnurses at 43, 53, and60–64years.Months since
birth until periods ceased naturally or because of hysterectomy
and bilateral oophorectomy (n  76), bilateral oophorectomy
only (n  2), hysterectomy and unilateral oophorectomy (n 
21), hysterectomy only (n  96), or for other reasons were ob-
tained. It was not possible to assign a date of menopause to
women who started HRT before the menopause and had not
come off HRT for at least a year when giving responses about
period regularity and the timing of the last period.
Age at menarche and length of reproductive life
Age at menarche was obtained from reports of the mother at
a medical examination and interview by a school doctor when
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the study member was aged about 14.5 years. For the 7% of
women who had not reached menarche by the time of this ex-
amination, retrospective reports obtained from the postal ques-
tionnaire at age 48 years were used instead. Length of reproduc-
tive life was derived by taking age at menarche from age at
natural menopause or hysterectomy (all in months since birth).
HRT use
From the dates of starting and stopping HRT, we derived an
ever-use ofHRT (yes vs no), length ofHRTuse in years, and time
since last use (within the last year, 1–5 y ago, more than 5 y ago).
Women who provided information on HRT use for at least five
of the 10 possible updates were included.
Other covariables
Height (centimeters) and weight (kilograms) were measured
according toa standardprotocol at the timeof thebone scansand
were standardized to give a mean of 0 and a SD of 1. Smoking at
age 60–64 years (yes/no) and main occupation (manual vs non-
manual) according to the Registrar General’s social class classi-
fication were also included as covariates.
Analysis
Stata version 12.0 was used for all analyses. Regressionmod-
els used natural logarithms of all bone variables for comparative
purposes (27). The coefficients from these models are presented
as the mean percentage difference in the bone parameter at
60–64 years between groups for categorical variables or the
per-unit change for continuous variables.
We first compared themean and SDs of the bone outcomes by
all of the reproductive and HRT indicators in the maximum
available samples.We then fitted three sets of regressionmodels.
All were first run unadjusted and then adjusted for height and
weight and then for smoking and adult occupation. First, for
women with a known age at period cessation, we used nested
regression models including type of period cessation, time since
period cessation, and the interaction between the two. This al-
lowed us to obtain separate estimates for the percentage differ-
ence in the bone outcomes for a 10-year difference in age at
naturalmenopause or age at hysterectomy.We then used similar
models to estimate a 10-year difference in length of reproductive
life for the natural and surgical menopause groups. Second, for
womenwith a known history ofHRT,we obtained estimates for
a 10-year difference in length of HRT use and then repeated this
analysis for age since last use. Third, for women with a known
age at period cessation and history of HRT, we repeated the first
set of regressionmodels additionally adjusted for HRT use. Sen-
sitivity analyseswere undertaken to seewhether any associations
between hysterectomy status and bone outcomes differed by oo-
phorectomy status.
Results
The initial sample comprised 848 women for whom type
of menopause was known and who had at least one mea-
sure from aDXAor pQCT scan at 60–64 years (Table 1).
Of these, 653women (77%)had anaturalmenopause and
195 (23%) had a hysterectomy and/or bilateral oopho-
rectomy (henceforth described as hysterectomy) before
the menopause. Age at period cessation was known for
709women; dateswere unknown for 134women because
of the timingof theirHRTuseand for fivewomenwhohad
a hysterectomy. Women who had a hysterectomy were
shorter and heavier and had greater vBMD, aBMD, and
SSI and strength at 60–64 years than women who had a
naturalmenopause. Themean age of period cessationwas
52.0 years for women who had a natural menopause and
44 years 6 months for women who had a hysterectomy.
Mean age at menarche, mean length of reproductive life,
and HRT use differed by type of menopause.
Unadjusted mean differences in bone size,
strength and BMD by age at menopause and
menarche, length of reproductive life, and
HRT use
Neither timing of naturalmenopause, age atmenarche,
nor length of natural reproductive life were associated
with CSA (diaphyseal or medullary) or SSI (Table 2).
Women who had an earlier natural menopause or a later
age at menarche had lower mean values of trabecular
vBMD, total vBMD, and spine and hip vBMD but not
cortical vBMD.Thosewith a shorter reproductive life had
lowermean values of trabecular vBMD, and spine and hip
aBMD but not cortical or total vBMD. Age at hysterec-
tomy was not associated with BMD, size, or SSI.
Length of HRT use was associated with lower medul-
lary CSA and was strongly and positively related to polar
SSI, cortical vBMD,and lumbar spine aBMD;associations
with total and trabecular vBMDand total hip aBMDwere
weaker (Table 2). Recent use of HRT was also associated
with polar SSI, cortical vBMD and total vBMD, and spine
aBMD. There were no associations with bone CSA at any
site.
Differences in bone outcomes per 10-year
difference in timing of period cessation (natural or
surgical) and length of reproductive life
Womenwhohada later naturalmenopausehada8.2%
(95% confidence interval [CI] 1.3%–15.1%, P  .02)
greater trabecular vBMD and a 6.0% (95% CI 0.5%–
11.5%, P .03) greater total vBMD thanwomenwith an
age of menopause 10 years earlier (Table 3, model 1).
There were no associations with age at hysterectomy (P
value for interaction between menopause type and age at
period cessation was .09 for trabecular vBMD and .02 for
total vBMD). Similar-sized estimates were seen for the
larger sample with spine and total hip aBMD. Adjust-
ments for current height and weight (Table 3, model 2),
adult occupation, and smoking had little effect on any of
these estimates.Womenwho had a hysterectomy had bet-
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Table 1. Characteristics of the Sample of 848 Women in the Medical Research Council NSHD With at Least One
Bone Measure and Known Type of Menopause
Total Sample Natural Menopause
Hysterectomy and/or
Bilateral Oophorectomy
P
Value
Maximum Sample 848a 653 195
pQCT Measures No Mean (SD) No Mean (SD) No Mean (SD)
Cortical sites: 50% radius
Diaphysis CSA, mm2 681 112.3 (15.8) 523 112.1 (15.5) 158 113.3 (16.8) .4
Medullary CSA, mm2 681 35.2 (12.5) 523 35.6 (12.5) 158 33.8 (12.3) .1
Polar SSI, mm3 682 210.6 (43.1) 524 208.6 (42.2) 158 217.2 (45.4) .03
Trabecular sites: 4% distal radius
Distal CSA, mm2 674 132.7 (23.9) 518 132.7 (24.5) 156 132.7 (22.0) .9
50% radius
Cortical vBMD, mg/cm3 682 1148.2 (39.4) 524 1146.8 (40.2) 158 1152.8 (36.3) .1
Distal radius (4%)
Trabecular vBMD, mg/cm3 673 171.7 (42.2) 517 169.7 (42.3) 156 178.3 (41.0) .02
Total vBMD, mg/cm3 674 329.3 (70.4) 518 325.5 (70.1) 156 342.0 (69.9) .01
DXA measures
Spine L1-L4 aBMD, g/cm2 843 .944 (.165) 649 .934 (.164) 194 .976 (.163) .002
Total hip aBMD, g/cm2 839 .869 (.131) 645 .859 (.132) 194 .902 (.123) .001
Current body size
Height, m 848 1.621 (.058) 653 1.624 (.058) 195 1.613 (.057) .03
Weight, kg 848 72.4 (14.1) 653 71.5 (14.1) 195 75.4 (14.0) .001
Reproductive measures
Age at period cessation, y 709 50 y 0 mo 519 52 y 0 mo 190 44 y 6 mo .001
(5 y 9 mo) (3 y 9 mo) (6 y 6 mo)
Age at menarche, y 688 13 y 0 mo 529 13 y 1 mo 159 12 y 10 mo .04
(1 y 7 mo) (1 y 3 mo) (1 y 4 mo)
Length of reproductive life 573 37 y 0 mo 418 38 y 10 mo 155 32 y 0 mo .001
(5 y 8 mo) (3 y 11 mo) (6 y 5 mo)
HRT use
Ever using HRT .001
No 277 36.40 247 42.22 30 17.05
Yes 484 63.60 338 57.78 146 82.95
Unknown 87 68 19
Last use of HRT .5
In the last year 63 13.24 40 12.05 23 15.97
1–5 y ago 72 15.13 50 15.06 22 15.28
More than 5 y ago 341 71.64 242 72.89 99 68.75
Taken HRT but last use unknown 8 6 2
Total length of HRT use, y .001
1 50 10.57 38 11.48 12 8.45
1–2 79 16.70 71 21.45 8 5.63
3–4 78 16.49 54 16.31 24 16.90
5–6 67 14.16 39 11.78 28 19.72
7–8 67 14.16 42 12.69 25 17.61
9–10 53 11.21 42 12.69 11 7.75
11–12 35 7.40 27 8.16 8 5.63
13 44 9.30 18 5.44 26 18.31
Unknown length 11 7 4
Current smoker
No 760 90.15 585 90.14 175 90.21 .9
Yes 83 9.85 64 9.86 19 9.79
Unknown 5 4 1
Adult social class
Nonmanual 680 80.28 534 81.90 146 74.87 .03
Manual 167 19.72 118 18.10 49 25.13
Unknown 1 1 0
a Sample excludes 13 women whose periods ceased because of medical treatment (eg, chemotherapy) and five women who had been
insufficiently followed up to determine menopause type.
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ter BMD than women who had a natural menopause (see
Supplemental Figure 1, A and B); the interaction with age
at period cessation meant that the differences were stron-
ger in women with a younger age at cessation. They also
had greater SSI (P .05). There were no associations be-
tween age at natural menopause or age at hysterectomy
and bone size or strength. The findings for length of re-
productive lifewere similar (SupplementalTable 1). There
was no evidence that the findings for hysterectomy status
differed by oophorectomy status.
Differences in bone outcomes per 10-year HRT use
and by time since last use
Length ofHRT (Table 4) and recency ofHRTuse (Sup-
plemental Table 2) were associated with greater SSI,
higher cortical and total and trabecular vBMD, and
Table 2. Mean and SD for Bone Outcomes at 60–64 Years by Menopausal Characteristics
Diaphysis
CSA, mm2
Mean (SD)
Medullary
CSA, mm2
Mean (SD)
Total vBMD,
mg/cm3
Mean (SD)
Trabecular
vBMD,
mg/cm3
Mean (SD)
Cortical
vBMD,
mg/cm3
Mean (SD)
Polar
SSI, mm3
Mean (SD)
Spine
L1-L4
aBMD,
g/cm3
Mean (SD)
Hip
aBMD,
g/cm3
Mean (SD)
Age at natural menopause, y
45 111.0 (19.6) 36.6 (13.2) 298.2 (73.2) 146.5 (36.2) 1139.9 (39.7) 204.7 (48.4) 0.85 (0.1) 0.83 (0.1)
45–49 109.7 (16.0) 37.1 (14.8) 314.5 (72.4) 167.0 (48.8) 1143.3 (44.1) 199.2 (38.4) 0.89 (0.2) 0.83 (0.1)
50–52 111.9 (14.5) 34.9 (12.1) 320.1 (64.5) 165.8 (40.3) 1149.6 (38.3) 211.8 (43.9) 0.92 (0.2) 0.86 (0.1)
53–55 112.2 (16.3) 36.2 (13.4) 331.7 (75.9) 171.5 (44.1) 1144.1 (41.8) 204.8 (43.2) 0.94 (0.2) 0.88 (0.1)
56–62 112.6 (17) 33.7 (11.1) 321.3 (54.8) 171.9 (35.4) 1149.9 (36.9) 211.9 (45.8) 0.98 (0.2) 0.89 (0.1)
P value for trenda .2 .3 .014 .004 .3 .2 .001 .001
Age at hysterectomy, y
40 115.3 (18) 33.5 (13.1) 337.1 (66.8) 178.1 (37.1) 1150.6 (28.8) 224.7 (47.4) 0.96 (0.2) 0.9 (0.1)
40–44 113.8 (17.8) 35.6 (12.8) 343.9 (60.6) 175.9 (44.3) 1152.4 (36.9) 216.8 (47.3) 0.95 (0.2) 0.9 (0.1)
45–49 112.1 (15.6) 32.1 (12.6) 341.2 (82.2) 179.8 (44.9) 1160 (34.1) 214 (41.5) 0.99 (0.2) 0.9 (0.1)
50 111.9 (16.4) 34.5 (11.1) 347.8 (66.6) 179.7 (37.8) 1144.4 (43.1) 213.5 (47.2) 0.99 (0.2) 0.89 (0.1)
P value for trenda .5 .7 .7 .9 .6 .3 .3 .9
Age at menarche, y
9–10 111.2 (12.5) 31.4 (9.01) 349.3 (84) 179.9 (40.1) 1158.5 (32.5) 213.2 (34.5) 0.98 (0.1) 0.9 (0.1)
11 113 (17.1) 34 (12.7) 339.2 (69.2) 176.7 (40.6) 1145.7 (44.2) 217.2 (45.1) 0.98 (0.2) 0.9 (0.1)
12 114.4 (16) 36.5 (13.2) 340.5 (74.6) 178.5 (46.1) 1145.9 (39.8) 213.1 (45) 0.95 (0.2) 0.87 (0.1)
13 111.5 (16) 35.7 (12.3) 320.9 (69.2) 169 (41.1) 1148.3 (40) 207.9 (42.5) 0.95 (0.2) 0.86 (0.1)
14 111.5 (14.4) 34.7 (11.9) 318.9 (63.8) 168.4 (34.9) 1151.4 (33) 207.5 (39) 0.92 (0.2) 0.85 (0.1)
15–19 111.9 (17.5) 34.7 (12.8) 336.8 (68.5) 157.7 (39.8) 1150.9 (39.7) 210.9 (38.5) 0.91 (0.2) 0.84 (0.1)
P value for trenda .4 .7 .03 .01 .9 .2 .004 .001
Length of natural reproductive life
35 109.9 (18.7) 37.3 (16.1) 305.1 (70.3) 155.5 (41.9) 1140.9 (44.2) 199.3 (41.3) 0.86 (0.1) 0.8 (0.1)
36–37 109.1 (14) 34.7 (11.2) 324.2 (72.1) 168.6 (46.9) 1152.5 (40.7) 204.6 (41.4) 0.91 (0.2) 0.84 (0.1)
38–39 112 (15.4) 35.5 (11) 323.9 (65.6) 173.4 (38.1) 1151.4 (32.5) 209.7 (46.8) 0.91 (0.2) 0.85 (0.1)
40–41 112.3 (15.9) 35.9 (14.3) 339.3 (69.1) 176.3 (41.1) 1142.9 (44.7) 207.1 (39.3) 0.97 (0.2) 0.9 (0.1)
42–43 116.3 (17.6) 35.9 (11.1) 319.7 (67.8) 165.1 (38.6) 1145.4 (31.6) 220.1 (47) 0.95 (0.2) 0.87 (0.1)
44 109.6 (12.5) 34.5 (8.8) 316.6 (63.5) 168.8 (38.4) 1148.2 (39.3) 198 (34.6) 0.98 (0.2) 0.88 (0.1)
P value for trenda .07 .9 .1 .02 .4 .07 .001 .001
Length of reproductive life (ceased surgically)
35 115.1 (16.4) 34.3 (12.5) 347 (70.3) 180.4 (44.9) 1154.6 (33.7) 221.4 (44.0) 0.97 (0.2) 0.90 (0.1)
36–37 115 (17.5) 38.4 (9.3) 318.4 (80.9) 179.6 (33.6) 1135.8 (35) 214.6 (53.8) 0.99 (0.2) 0.90 (0.1)
38–39 109.5 (14.2) 32.2 (11.5) 344.2 (66.3) 177.7 (45.3) 1151.8 (40.2) 213.7 (39.9) 0.95 (0.2) 0.86 (0.1)
40–41 102.6 (7.2) 24.5 (5) 405.8 (67.2) 204.6 (13.4) 1192.8 (20.9) 184.0 (7.9) 1.09 (0.01) 1.01 (0.1)
42–43 104.9 (17.8) 27.3 (8.3) 391.3 (46.6) 192.7 (21.5) 1169.6 (27.4) 198.4 (43.9) 1.1 (0.2) 0.90 (0.1)
44 122.7 (12.2) 42.9 (16.3) 317.1 (89.3) 159.1 (57.8) 1108.9 (77.5) 235.2 (49.7) 0.92 (0.2) 0.88 (0.1)
P value for trend .01 .2 .7 .7 .9 .02 .9 .7
Length of HRT use, y
13 118.6 (17) 35.4 (13.9) 348.4 (66.4) 174.5 (37.8) 1165.2 (38.7) 236.6 (49.1) 1.01 (0.2) 0.90 (0.1)
11–12 111.9 (12.3) 32.7 (8.17) 337.6 (66.8) 179.2 (35.7) 1161.5 (32.1) 215.1 (33.5) 0.94 (0.1) 0.88 (0.1)
9–10 111.3 (14.2) 32 (8.95) 335.5 (67.2) 175.1 (37.6) 1156.8 (35.2) 213.9 (43.5) 0.95 (0.2) 0.86 (0.1)
7–8 113.8 (13.7) 33.6 (11) 334.1 (70.8) 178.5 (40.3) 1152.8 (34.7) 216.6 (35) 0.95 (0.1) 0.87 (0.1)
5–6 112.3 (16.4) 35.7 (13.4) 316.7 (64.6) 168.1 (38.9) 1141.1 (38) 211.9 (46.3) 0.97 (0.2) 0.87 (0.1)
3–4 113.3 (16.1) 34.8 (12.4) 340.1 (73.4) 175.6 (43.8) 1146.9 (38) 213.5 (41) 0.96 (0.2) 0.88 (0.1)
1–2 114.1 (17.4) 36.4 (14.3) 334.6 (81.9) 177.9 (51.4) 1144 (45.7) 212.6 (48.7) 0.94 (0.2) 0.88 (0.1)
1 111.4 (13.1) 35.1 (9.44) 326.4 (66.2) 170.3 (39.7) 1145 (39) 204.4 (39.9) 0.95 (0.2) 0.86 (0.1)
Never used HRT 111.7 (16.4) 36.3 (13.2) 323.7 (66.7) 167.5 (40.2) 1146.7 (38.6) 207 (43.4) 0.92 (0.2) 0.86 (0.1)
P value for trenda .1 .03 .07 .07 .001 .001 .002 .1
Last HRT use
In the last year 115 (15.2) 33.1 (12) 354.1 (65.5) 175.7 (35) 1165.8 (33.8) 226.1 (45.6) 1.01 (0.1) 0.9 (0.1)
1–5 y ago 114.1 (14.6) 33.9 (10.9) 343.8 (69.8) 174.4 (41.7) 1152.2 (34.6) 217.2 (46.4) 0.94 (0.2) 0.85 (0.1)
5 y ago 112.6 (15.5) 35 (12.1) 326.9 (70.9) 174.8 (42.9) 1146.5 (39.8) 211.5 (41.5) 0.95 (0.2) 0.87 (0.1)
Never used HRT 111.7 (16.4) 36.3 (13.2) 323.7 (66.7) 167.5 (40.2) 1146.7 (38.6) 207 (43.4) 0.92 (0.2) 0.86 (0.1)
P value (category)a .4 .2 .01 .2 .007 .02 .001 .1
a Tests for trend or categories were based on regression models in which bone outcomes were logged, and age at period cessation and length of
reproductive life and length of HT use were included as months since birth.
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greater aBMD, particularly in the lumbar spine; in some
cases the estimates strengthened after adjusting for meno-
pausal type (Table 4, model 2) and current height and
weight (Table 4, model 3). For example, in the adjusted
model, a 10-year difference in HRT use was associated
witha6.3%(95%CI3.1%–9.4%,P .001) greaterpolar
SSI and a 0.9% (95% CI 0.3%–1.5%, P  .002) greater
cortical vBMD. Further adjustment (data not shown) for
smoking and adult occupation did not change these esti-
mates. The association between length of HRT use and
spineaBMDdifferedby typeofmenopause (Pvalue for the
interaction  .02), in that the association was less pro-
nounced in those who had a hysterectomy compared with
those with a natural menopause (Table 4 and Supplemen-
tal Table 2).
Differences in bone outcomes per 10-year
difference in timing of period cessation (natural or
surgical) or length of reproductive life,
additionally adjusted for HRT use
After additional adjustment for length of HRT use,
women with a later natural menopause still had greater
trabecular vBMD and aBMD (Table 5 and Supplemental
Table 3). Length of HRT use and recent HRT use re-
mainedpositively associatedwith SSI, cortical vBMD, and
aBMD, particularly of the lumbar spine. Similar results
were seen for length of reproductive life (Supplemental
Tables 4 and 5).Womenwho had a hysterectomy still had
higherBMDafter these adjustments thanwomenwhohad
anaturalmenopause.The interactionbetweenmenopause
type and HRT use on lumbar spine was weaker (P  .1)
than in themodels in Table 4 (and Supplemental Table 2).
Discussion
We have shown in a large British cohort of women that a
10-year later age at natural menopause was associated
with an estimated 6%–8% greater trabecular vBMD in
women aged 60–64 years, even after adjusting for body
size, HRT use, and social and behavioral factors. A longer
length of reproductive life showed similar consistent and
positive associationswith the sameboneparameters.HRT
use was associated with a 0.9% greater cortical vBMD,
6.3% smaller medullary CSA, and a 6% greater SSI; the
associations with total and trabecular vBMD were
weaker. Age at naturalmenopause, length of reproductive
life, andHRTuse inwomenwhohadanaturalmenopause
Table 3. Percentage Difference in Bone Outcomes per 10 Years of Difference in Timing of Period Cessation
(Natural/Surgical), Adjusted for Type of Menopause, and Then Additionally Adjusted for Current Height and Weight
Model 1 Model 2
Adjusted for Type of Menopause
Model 1  Adjusted for Current
Height and Weight
Difference,
% 95% CI
P
Value
Difference,
% 95% CI
P
Value
Diaphysis CSA (n  562)
Age at natural menopause 2 1.6 to 5.7 .3 0.8 2.5 to 4.1 .6
Age at hysterectomy 1.3 4.6 to 2.1 .5 0.2 3.2 to 2.8 .9
Medullary CSA (n  561)
Age at natural menopause 4.8 13.9 to 4.4 .3 6.1 15.1 to 2.8 .2
Age at hysterectomy 1.7 6.7 to 10.1 .7 3 5.2 to 11.3 .5
Total vBMD (n  555)
Age at natural menopause 6 0.5–11.5 .03 5.9 0.5–11.4 .03
Age at hysterectomy 0.8 4.2 to 5.8 .8 0.7 4.3 to 5.6 .8
Trabecular vBMD (n  554)
Age at natural menopause 8.2 1.3–15.1 .02 8.2 1.4–15.0 .02
Age at hysterectomy 0.1 6.2 to 6.4 .9 0.2 6.4 to 6.1 .9
Cortical vBMD (n  563)
Age at natural menopause 0.5 0.4 to 1.4 .3 0.5 0.4 to 1.4 .3
Age at hysterectomy 0.2 1.1 to 0.6 .6 0.2 1 to 0.6 .6
Polar SSI (n  563)
Age at natural menopause 3.7 1.7 to 9.1 .2 2.1 2.8 to 6.9 .4
Age at hysterectomy 2.8 7.7 to 2.1 .23 1.4 5. to 3.1 .5
Lumbar spine aBMD (n  703)
Age at natural menopause 9.3 5.3–13.3 .001 8.8 5.1–12.6 .001
Age at hysterectomy 1.8 2.0 to 5.6 .4 2.29 1.3 to 5.8 .2
Total hip aBMD (n  700)
Age at natural menopause 6.7 3.2–10.3 .001 6.4 3.4–9.4 .001
Age at hysterectomy 0.04 3.3 to 3.2 .9 0.4 2.4 to 3.2 .8
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were also associated with aBMD of the lumbar spine and
total hip.
Comparison with other studies and interpretation
Natural menopause, length of reproductive life,
and bone
Previous studies have shown that an earlier natural
menopause and a shorter reproductive life are associated
with lower BMD (2, 4, 6, 8). Using transilial biopsy spec-
imens, Akhter et al (28) observed that across the meno-
pause transition, there was decreasing bone tissue volume
to total volume and trabecular number and increased tra-
becular spacing, which would explain the changes in mi-
croarchitecture detected as lower BMD using DXA or
pQCT. Our findings show that the inverse associations
with earlymenopause and shorter reproductive life persist
into the seventh decade of life and are observed for vBMD
and aBMD. Whether these effects will eventually be at-
tenuated by age as a risk factor for fracture and so have
little long-term effect on hip fracture risk, as indicated in
theMillionWomen Study (16), cannot yet be determined,
but our study has one of the longest follow-up periods
to date.
There is a need to separate age- andmenopause-related
mechanisms that affect bone health. Although the loss of
BMD is initially in the trabecular compartment and in
women is most strongly related to menopause, it is fol-
lowed by an equivalent decline in cortical vBMD because
endo- and intracortical resorption accelerates and perios-
teal expansion slows, leading to a reduction in cortical
area, and consequently in bone strength (29). Factors
other than declining sex hormonesmay play a greater role
in this aspect of bone loss and may explain why the asso-
ciations between naturalmenopause and reproductive life
and bone differed from the associations evident for
HRT use.
Our finding that a shorter reproductive life was asso-
ciated with lower BMD suggests that lifetime cumulative
estrogen exposure may be important. In determining the
duration of endogenous estrogens, Hagemans et al (30)
concluded that knowing age at menarche and menopause
was sufficient; having information on parity, miscar-
riages, lactation, oral contraceptive use, and length of
menstrual cycle did not explain any further variation in
BMD, adding strength to the observations in the current
study. Various other factors that we are unable to study
will contribute to menopausal bone loss such as declining
levels of estradiol and FSH (31), cytokines (32), genetic
factors (33), and bone, muscle, and fat interactions (34).
Table 4. Percentage Difference in Bone Outcomes per 10 Years of HRT Use, Unadjusted, and Then Adjusted for
Type of Menopause and Additionally Adjusted for Current Height (Meters) and Weight (Kilograms)
Unadjusted
Model 2 Model 3
Adjusted for Type of
Menopause
Adjusted for Type of
Menopause, Height and Weight
Difference,
% 95% CI
P
Value
Difference,
% 95% CI
P
Value
Difference,
% 95% CI
P
Value
Diaphysis CSA
(n  603)
1.9 0.4 to 4.2 .1 1.8 0.6 to 4.2 .1 2.4 0.3–4.5 .03
Medullary CSA
(n  602)
6.5 12.2 to 0.7 .03 5.7 11.7 to 0.2 .06 5.5 11.4 to 0.4 .07
Total vBMD
(n  597)
3.3 0.3 to 6.8 .07 2.3 1.3 to 6 .2 3.0 0.6 to 6.7 .1
Trabecular vBMD
(n  596)
4.0 0.3 to 8.3 .07 2.9 1.6 to 7.3 .2 3.8 0.6 to 8.2 .09
Cortical vBMD
(n  604)
0.9 0.4–1.5 .001 0.9 0.3–1.5 .003 0.9 0.3–1.5 .002
Polar SSI
(n  604)
6.0 2.6–9.3 .001 5.4 1.9–8.9 .003 6.3 3.1–9.4 .001
Spine L1-L4
aBMD
(n  747)
4.0 1.4–6.5 .002
Ceased
naturally
5.3 2.1–8.5 .001 6.7 3.7–9.7 .001
Ceased
surgically
1.4 6.1 to 3.2 .5 0.6 3.9 to 5.0 .8
Hip aBMD
(n  742)
1.8 0.4 to 3.9 .1 0.7 1.5 to 3 .5 2.8 0.8–4.7 .007
P  .02 for the interaction between type of menopause and length of HRT.
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HRT use and bone
Randomized control trials have shown increased
aBMD in hip and lumbar spine and protection from frac-
ture in HRT users (13, 14, 35–39). Our finding of greater
aBMD for HRT users, particularly in the lumbar spine, a
site containing mostly trabecular bone, is consistent with
these findings,
Findings from our study of the short-term benefits of
HRT on bone are likely to be due to the mechanism by
which it acts: increased cortical vBMD and a narrower
medullary cavity are likely to be due to reductions in both
intracortical remodeling and endocortical resportion,
both of which would increase bone strength. The findings
support the view that HRT protects cortical bone from
age-related changes in endocortical resorption and re-
duced bone turnover. Previous smaller studies have also
shown that HRT users compared with nonusers have
higher vBMD, larger cortical CSA, and greater bending
and compressive bone strength in the tibial shaft, aweight-
bearing site, as well as the distal radius (40, 41), which is
consistentwith our findings. A small longitudinal study of
HRT users compared with a control group suggested that
Table 5. Percentage Difference in Bone Outcomes by Type of Menopause per 10 Year Difference in Timing of
Period Cessation (Natural or Surgical), per 10-Year Difference in HRT Use, Height, Weight, Smoking, and Adult
Occupation
Diaphysis CSA
(n  508)a
Medullary CSA
(n  507)a
Total vBMD, mg/cm3
(n  502)a
Trabecular vBMD, mg/cm3
(n  501)a
Difference,
% 95% CI
P
Value
Difference,
% 95% CI
P
Value
Difference,
% 95% CI
P
value
Difference,
% 95% CI
P
Value
Hysterectomy vs
natural
menopause
(at age 50 y)
0.5 2.7 to 3.7 .8 3.1 11.8 to 5.6 .5 5.8 0.5–11 .03 5.8 0.8 to 12.4 .08
Age at period
cessation,
per 10 y
Ceased
naturally
0.1 3.4 to 3.5 .9 8.5 17.9 to 0.9 .08 3.7 2 to 9.4 .2 7.1 0.04–14.2 .05
Ceased
surgically
0.3 3.6 to 3 .8 0.5 8.4 to 9.4 .9 2.4 3 to 7.8 .4 1.5 5.2 to 8.2 .7
HRT use, per
10 y
2.3 0.3 to 4.9 .08 6.3 13.4 to 0.8 .08 2.5 1.8 to 6.8 .3 4.0 1.4 to 9.3 .1
Height, per 1 SD) 5.1 3.9 to 6.2 .001 7.5 4.5 to 10.5 .001 2.5 4.3 to 0.7 .008 4.0 6.3 to 1.8 .001
Weight, per 1 SD) 2.9 1.8 to 4.1 .001 0.3 2.9 to 3.4 .9 4.2 2.3–6.1 .001 5.7 3.3 to 8 .001
Smoking vs not
smoking
1.1 2.7 to 4.9 .6 2.1 8.2 to 12.4 .7 0.7 5.6 to 7 .8 1.2 9 to 6.7 .8
Manual vs
nonmanual
social class
0.5 3.4 to 2.3 .7 1.6 6.1 to 9.3 .7 0.6 5.4 to 4.1 .8 0.9 4.9 to 6.7 .8
Cortical vBMD
(n  509)a
Polar SSI
(n  509)a
Lumbar Spine aBMD
(n  635)a
Total Hip aBMD
(n  632)a
Difference,
% 95% CI
P
Value
Difference,
% 95% CI
P
Value
Difference,
% 95% CI
P
Value
Difference,
% 95% CI
P
Value
Hysterectomy vs
natural
menopause
0.2 0.7 to 1 .7 2.9 1.8 to 7.6 .2 6.0 2.3 to 9.8 .002 3.7 0.8 to 6.7 .01
Age at period
cessation,
per 10 y
Ceased
naturally
0.5 0.4 to 1.4 .3 1.0 4.1 to 6.1 .7 8.8 4.8 to 12.7 .001 5.8 2.6 to 8.9 .001
Ceased
surgically
0.2 0.7 to 1.1 .6 0.1 4.9 to 4.8 .9 3.3 0.5 to 7.1 .09 1.6 1.4 to 4.6 .3
HRT use, per
10 y
0.9 0.2 to 1.6 .01 6.3 2.5 to 10.2 .001 3.6 0.5 to 6.6 .02 2.7 0.3 to 5.1 .03
Height, per
1 SD
0.01 0.3 to 0.3 .9 6.7 5.1 to 8.4 .001 0.7 0.6 to 2 .3 0.4 1.4 to 0.7 .5
Weight, per
1 SD
0.3 0.03 to 0.6 .07 4.5 2.8 to 6.2 .001 6.2 4.9 to 7.5 .001 8.1 7.1 to 9.2 .001
Smoking vs not
smoking
0.2 1.3 to 0.8 .6 1.0 4.6 to 6.6 .7 2.2 6.7 to 2.3 .3 3.2 6.9 to 0.4 .09
Manual vs
nonmanual
social class
0.3 1.1 to 0.4 .4 3.2 7.4 to 1 .1 0.6 3.9 to 2.6 .7 1.1 3.7 to 1.5 .4
a Samples exclude between 53 and 68 women with insufficient data on HRT use.
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exogenous estrogen fills the small marrow pores close to
the endocortical surface so that the pQCT-defined bound-
ary between trabecular and cortical bone shifted in favor
of cortical bone, conferring greater strength to the bone
(22).Mikkola et al (18) carried out a long-term follow-up
of monozygotic twin pairs and showed greater cortical
and trabecular vBMD at distal and diaphyseal sites in the
twin taking HRT compared with the other twin who was
not; these differences resulted in greater compressive and
bending strength. They suggested that HRT may become
more important with years from menopause as the study
showed an annual increase of 2.6%–2.8% in intrapair
difference in bone strength. Given the results of these two
studies, it was surprising that we did not find an effect of
HRT on trabecular or total BMD at the distal radius. This
may be due to limitations in the spatial resolution of
pQCT, meaning we could not accurately define the cor-
tical, subcortical, and trabecular boundaries and so detect
differences in the bone compartments.
Hysterectomy status and bone
Women in this cohort who had a hysterectomy had
greater BMD thanwomenwith a natural menopause. The
difference was greatest for women who had an earlier age
at period cessation. It was reduced in the models that in-
cluded all women in whom use of HRT was known, sug-
gesting that longer use of HRT contributed to greater
BMD in women with a hysterectomy. These women were
also of heavier weight, and previous NSHD studies have
shown they were also more likely to be overweight or
obese in midlife and have an earlier menarche (42, 43). So
these factors too may partly explain the association. The
most common reason for a hysterectomy, particularly at
earlier ages, was fibroids (43), which may have been as-
sociated with greater estrogen exposure through earlier
menarche, and contributed to greater BMD. There is little
evidence from other studies that hysterectomy or oopho-
rectomy is associated with bone outcomes or fracture risk
(9–12), although few studies have examined the reasons
for the operations, which may be of consequence (11).
Strengths and limitations
The main strengths of this study are the prospective,
detailed, and longitudinal collection of data on meno-
pausal characteristics in relation to gold standard bone
outcomes on a relatively large sample of British women
followed up into early old age. pQCT and DXAmeasure-
ments were obtained; pQCT enables the investigation of
bone size, strength, and vBMD of trabecular and cortical
compartments with less confounding by body size, which
is a limitation of aBMD obtained by DXA. That all the
women were born in the same week, and that the scans
took place over a narrow age range of 10 years after the
average age at menopause, limited potential confounding
by age and enabled an assessment of the persistence of
menopause-related effects on bone. It also allowed the
study of howHRT usemay protect from fracture through
slowing down age-related changes in vBMD and endo-
cortical resportion that decrease bone strength.
A limitation is that we did not collect HRT dose, and
data on types of HRT preparations were insufficiently
complete to use.We have previously reported that the vast
majority on HRT who had had a hysterectomy were tak-
ing estrogen alone, whereas other women were taking a
combined preparation (44). Data on length of use and age
at last use were advantages over studies that have only
collected measures of current and past HRT use. Another
limitation is that the sample was all born in the early post-
war period; our findings may not be generalizable to later
born cohorts.Whereas these cohorts have experienced lit-
tle change in the timing of natural menopause, HRT use
has declined since the adverse reports from clinical trials,
and there has been a small decline in pubertal timing (45).
HRTuse in this cohort showedadistinctdropduring2002
(age 56 y) at the time of adverse trial reports (46). In this
context, HRT prescriptions for participants whose peri-
ods ceased from this time (who were more likely to have
greaterBMD)were less likely,whereasHRTmay still have
been prescribed to women seen to be at high risk of frac-
ture (including those with early period cessation). Thus,
the associations between HRT use and BMD could have
been weakened.
In conclusion, this study shows that later naturalmeno-
pause and longer reproductive life are associated with
greater trabecular vBMD and aBMD in early old age and
that HRT use is associated with greater cortical vBMD,
bone strength, and aBMD. Although HRT is not likely to
be restored as an agent for common use primarily for the
prevention of osteoporosis, this study showed protective
effects on bone forwomenwith naturalmenopause taking
the therapy.
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